Printer Friendly

SENETEK PLC ANNOUNCES APPROVAL TO BEGIN FORMAL CLINICAL TRIALS OF MALE SEXUAL DYSFUNCTION PRODUCT

 ST. LOUIS, May 3 /PRNewswire/ -- Senetek PLC (NASDAQ: SNTKY) through its President and CEO, Dr. Gerloff Homan announced that the Danish Health Authorities have given approval to start shortened formal clinical trials of Senetek's proprietary Male Sexual Dysfunction Product.
 Senetek expects successful completion of the formal clinical trials and commercial sale of this product in the first quarter of 1994.
 The above is based on 2-1/2 years of successful tests of Senetek's Male Sexual Dysfunction Product with no side effect.
 Dr. Homan further stated that Senetek has received formal notice from the U.S. Patent Office of the allowance of the broad claims relating to Senetek's Male Sexual Dysfunction Product.
 Extensive testing of this product is presently under way in selected European countries.
 -0- 5/3/93
 /CONTACT: Dennis Nebbe of Senetek, 800-869-1696/
 (SNTKY)


CO: Senetek PLC ST: Missouri IN: MTC SU:

RA-BR -- AT020 -- 3785 05/03/93 12:20 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 3, 1993
Words:152
Previous Article:NATIONAL LAW JOURNAL TAKES A 5-YEAR LOOK AT LAWYERS' SALARIES
Next Article:MERRY LAND BUYS JACKSONVILLE PROPERTY
Topics:


Related Articles
SENETEK GETS U.S. PATENT ON MALE SEXUAL DYSFUNCTION DRUG
SENETEK RECEIVES NOTICE FROM ORTHO PHARMACEUTICAL
SENETEK TO ADVANCE TIME SCHEDULE FOR MARKETING MALE SEXUAL DYSFUNCTION PRODUCT
SENETEK ANNOUNCES NEW DIVISION PRESIDENT OF RESEARCH AND DEVELOPMENT
SENETEK GRANTED OKAY FOR BRITISH CLINICAL TRIALS OF VASOPOTIN
Senetek PLC reports encouraging results from Phase III clinical trials of INVICORP, its new drug therapy for Erectile Dysfunction
British Study Shows Senetek's INVICORP Was 24% More Effective Than PGE1 in Treating Erectile Dysfunction
Senetek files Product Licensing Application, seeking approval to market its INVICORP therapy for erectile dysfunction in Europe
Senetek Files Second Product Licensing Application, Seeking Approval to Market Its INVICORP(TM) Therapy for Erectile Dysfunction in Denmark
Senetek Files Third Product Licensing Application (PLA); Seeks Approval To Market Its INVICORP Therapy for Erectile Dysfunction in Ireland

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters